Jagsonpal Pharmaceuticals share price
You have to be logged in to add this to Watchlist.- ₹245.45(6.81%)July 11, 2025 14:05:23 PM IST
- NSE
- BSE
- Vol : 800.46K (NSE + BSE)Last 20 day avg : 83.85 K
Jagsonpal Pharmaceuticals is trading 6.81% upper at Rs 245.45 as compared to its last closing price. Jagsonpal Pharmaceuticals has been trading in the price range of 249.60 & 228.95. Jagsonpal Pharmaceuticals has given -5.71% in this year & 0.25% in the last 5 days. Jagsonpal Pharmaceuticals has TTM P/E ratio 26.50 as compared to the sector P/E of 22.90.The company posted a net profit of 6.58 Crores in its last quarter.Listed peers of Jagsonpal Pharmaceuticals include Neuland Laboratories (2.97%), Unichem Laboratories (-1.18%), Jagsonpal Pharmaceuticals (6.81%).The Mutual Fund holding in Jagsonpal Pharmaceuticals was at 0.11% in 30 Sep 2024. The MF holding has - from the last quarter. The FII holding in Jagsonpal Pharmaceuticals was at 2.10% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jul 11, 2025, 08:37 AM UTC
- Dividend YieldInline with the industry1.08Annual dividends as a percentage of the stock price.
- P/BHigher than historical values6.39The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values28.21Price-to-earnings ratio based on trailing 12-month earnings
- BetaMedium volatility0.92Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.04The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 34.66% from Rs 58.56 crore to Rs 43.49 crore, year-on-year
- The company has grown its March quarter profit by 85.49% from Rs 3.55 crore to Rs 6.58 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 232.20
- R2
- 240.70
- R3
- 249.00
- S1
- 215.40
- S2
- 207.10
- S3
- 198.60
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Neuland Laboratories | Moderately Bullish | 12,255.50 | 2.97 | 15,726.49 | 73.84 | 9.82 | 0.10 | 7.17 |
| Unichem Laboratories | Bearish | 591.35 | -1.18 | 4,176.91 | 30.01 | 1.68 | - | 3.51 |
| Jagsonpal Pharmaceuticals | Bullish | 245.45 | 6.81 | 1,626.88 | 38.93 | 6.36 | 0.87 | 3.18 |
| Themis Medicare | Bearish | 124.00 | -0.24 | 1,141.30 | 38.82 | 2.88 | 0.40 | 4.62 |
| Ind-swift Laboratories | Neutral | 105.00 | -0.62 | 639.52 | 4.86 | 0.73 | - | 1.20 |
- Promoter(s) holds a high stake in the company at 67.78%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding is constant over the last quarter at 2.10%
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-06 | Audited Results & Final Dividend |
| 2025-01-22 | Quarterly Results |
| 2024-10-23 | Quarterly Results & Stock Split |
| 2024-08-07 | Quarterly Results |
| 2024-05-20 | Audited Results & Final Dividend |
- IndustryMajor Drugs
- ISININE048B01035
- BSE Code507789
- NSE CodeJAGSNPHARM
Jagsonpal Pharmaceuticals is trading at 245.45 as on Fri Jul 11 2025 08:35:23. This is 6.81% upper as compared to its previous closing price of 229.80.
The market capitalization of Jagsonpal Pharmaceuticals is 1626.88 Cr as on Fri Jul 11 2025 08:35:23.
The 52 wk high for Jagsonpal Pharmaceuticals is 328.02 whereas the 52 wk low is 131.22
Jagsonpal Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 26.50
- Sector P/E: 22.90
- Dividend Yield: 1.09%
- D/E ratio: 0.04
Jagsonpal Pharmaceuticals reported a net profit of 55.36 Cr in 2025.
The Mutual Fund Shareholding was 0.11% at the end of 30 Sep 2024.